For three of the four assays used for PD-L1 therapy of non-small cell lung cancer (NSCLC) and as detailed below, the negative or positive PD-L1 status of the patient is set by comparing this percentage to an assay specific cut-off value4. The gene discussed is CD274; the disease is non-small cell lung carcinoma.